PL2420256T3 - Terapia genowa dla zaburzeń neurometabolicznych - Google Patents

Terapia genowa dla zaburzeń neurometabolicznych

Info

Publication number: PL2420256T3
Authority: PL; Poland
Prior art keywords: disorders; disease; nervous system; central nervous; gene therapy
Prior art date: 2005-05-02

Application number

PL11169633.2T

Other languages

English (en)

Inventor

Marco A. Passini

James Dodge

Gregory R Stewart

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-02

Filing date

2006-05-02

Publication date

2016-12-30

2006-05-02 Application filed filed Critical

2016-12-30 Publication of PL2420256T3 publication Critical patent/PL2420256T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14041—Use of virus, viral particle or viral elements as a vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Virology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Obesity (AREA)
Diabetes (AREA)
Hematology (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)

PL11169633.2T 2005-05-02 2006-05-02 Terapia genowa dla zaburzeń neurometabolicznych PL2420256T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US67705705P	2005-05-02	2005-05-02
US68580805P	2005-05-31	2005-05-31

Publications (1)

Publication Number	Publication Date
PL2420256T3 true PL2420256T3 (pl)	2016-12-30

Family

ID=37308324

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PL06759081T PL1879624T3 (pl)	2005-05-02	2006-05-02	Terapia genowa dla zaburzeń neurometabolicznych
PL11169633.2T PL2420256T3 (pl)	2005-05-02	2006-05-02	Terapia genowa dla zaburzeń neurometabolicznych
PL16162716T PL3058959T3 (pl)	2005-05-02	2006-05-02	Terapia genowa dla zaburzeń neurometabolicznych
PL19153520T PL3520823T3 (pl)	2005-05-02	2006-05-02	Terapia genowa zaburzeń neurometabolicznych

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL06759081T PL1879624T3 (pl)	2005-05-02	2006-05-02	Terapia genowa dla zaburzeń neurometabolicznych

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PL16162716T PL3058959T3 (pl)	2005-05-02	2006-05-02	Terapia genowa dla zaburzeń neurometabolicznych
PL19153520T PL3520823T3 (pl)	2005-05-02	2006-05-02	Terapia genowa zaburzeń neurometabolicznych

Country Status (13)

Country	Link
US (2)	US10632213B2 (pl)
EP (4)	EP3520823B1 (pl)
JP (3)	JP5829372B2 (pl)
CN (4)	CN107007842A (pl)
AT (1)	ATE525092T1 (pl)
AU (1)	AU2006243776A1 (pl)
BR (1)	BRPI0611379A2 (pl)
CA (2)	CA2607173C (pl)
ES (1)	ES2887076T3 (pl)
IL (2)	IL187078A (pl)
PL (4)	PL1879624T3 (pl)
PT (4)	PT3058959T (pl)
WO (1)	WO2006119458A1 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1879623T3 (da) *	2005-05-02	2012-12-17	Genzyme Corp	Genterapi til rygmarvssygdomme
WO2006119458A1 (en)	2005-05-02	2006-11-09	Genzyme Corporation	Gene therapy for neurometabolic disorders
MX364444B (es)	2006-06-07	2019-04-26	Genzyme Corp	Terapia génica para esclerosis lateral amiotrófica y otros trastornos de la médula espinal.
PT2158322T (pt)	2007-06-06	2017-08-09	Genzyme Corp	Terapia genética para doenças do armazenamento lisossomal
US8735082B2 (en)	2008-11-10	2014-05-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Gene signature for predicting prognosis of patients with solid tumors
RS62779B1 (sr)	2009-05-02	2022-01-31	Genzyme Corp	Genska terapija neurodegenerativnih poremećaja
US9150926B2 (en)	2010-12-06	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Diagnosis and treatment of adrenocortical tumors using human microRNA-483
WO2012145646A1 (en) *	2011-04-20	2012-10-26	Miguel Sena-Esteves	Methods for the treatment of tay-sachs disease, sandhoff disease, and gmi-gangliosidosis
EP3151866B1 (en)	2014-06-09	2023-03-08	Voyager Therapeutics, Inc.	Chimeric capsids
CA2966620A1 (en)	2014-11-05	2016-05-12	Voyager Therapeutics, Inc.	Aadc polynucleotides for the treatment of parkinson's disease
CA2967367C (en)	2014-11-14	2023-05-16	Voyager Therapeutics, Inc.	Compositions and methods of treating amyotrophic lateral sclerosis (als)
MX2017006217A (es)	2014-11-14	2018-05-02	Voyager Therapeutics Inc	Polinucleotidos moduladores.
WO2016081924A1 (en) *	2014-11-20	2016-05-26	Duke University	Compositions, systems and methods for cell therapy
EP3230441A4 (en)	2014-12-12	2018-10-03	Voyager Therapeutics, Inc.	Compositions and methods for the production of scaav
PT3256594T (pt) *	2015-02-10	2022-01-18	Genzyme Corp	Entrega intensificada de partículas virais ao corpo estriado e córtex
CN112472796A (zh) *	2015-03-26	2021-03-12	苏州澳宗生物科技有限公司	使用p75ecd和/或p75诊断或治疗神经障碍的方法
GB201508025D0 (en)	2015-05-11	2015-06-24	Ucl Business Plc	Fabry disease gene therapy
US11027024B2 (en)	2015-05-29	2021-06-08	University Of Iowa Research Foundation	Methods of delivery of transgenes for treating brain diseases
US11299751B2 (en)	2016-04-29	2022-04-12	Voyager Therapeutics, Inc.	Compositions for the treatment of disease
WO2017189959A1 (en)	2016-04-29	2017-11-02	Voyager Therapeutics, Inc.	Compositions for the treatment of disease
CA3024449A1 (en)	2016-05-18	2017-11-23	Voyager Therapeutics, Inc.	Compositions and methods of treating huntington's disease
CA3024448A1 (en)	2016-05-18	2017-11-23	Voyager Therapeutics, Inc.	Modulatory polynucleotides
EP3831281A1 (en)	2016-08-30	2021-06-09	The Regents of The University of California	Methods for biomedical targeting and delivery and devices and systems for practicing the same
JOP20190200A1 (ar)	2017-02-28	2019-08-27	Univ Pennsylvania	تركيبات نافعة في معالجة ضمور العضل النخاعي
SG11201909870SA (en)	2017-05-05	2019-11-28	Voyager Therapeutics Inc	Compositions and methods of treating amyotrophic lateral sclerosis (als)
MX2019013172A (es)	2017-05-05	2020-09-07	Voyager Therapeutics Inc	Composiciones y metodos para tratar la enfermedad de huntington.
IL271193B1 (en)	2017-06-07	2024-09-01	Regeneron Pharma	Preparations and methods for internalizing enzymes
JOP20190269A1 (ar)	2017-06-15	2019-11-20	Voyager Therapeutics Inc	بولي نوكليوتيدات aadc لعلاج مرض باركنسون
AU2018302016A1 (en)	2017-07-17	2020-02-06	The Regents Of The University Of California	Trajectory array guide system
EP3662060A2 (en)	2017-08-03	2020-06-10	Voyager Therapeutics, Inc.	Compositions and methods for delivery of aav
US20200237799A1 (en)	2017-10-16	2020-07-30	Voyager Therapeutics, Inc.	Treatment of amyotrophic lateral sclerosis (als)
TW202413649A (zh)	2017-10-16	2024-04-01	美商航海家醫療公司	肌萎縮性脊髓側索硬化症(als)之治療
KR20240126916A (ko) *	2023-02-14	2024-08-22	경북대학교 산학협력단	Asm 단백질 또는 이의 단편을 포함하는 퇴행성 신경질환 또는 우울증 예방 또는 치료용 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8303626D0 (sv)	1983-06-23	1983-06-23	Kabigen Ab	A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced
US5672344A (en)	1987-12-30	1997-09-30	The Regents Of The University Of Michigan	Viral-mediated gene transfer system
US5773278A (en)	1991-05-03	1998-06-30	Mount Sinai Medical Center	Acid sphingomyelinase gene
AU687829B2 (en)	1993-06-24	1998-03-05	Advec, Inc.	Adenovirus vectors for gene therapy
PT797676E (pt)	1993-10-25	2006-05-31	Canji Inc	Vector adenoviral recombinante e metodos de utilizacao
PT733103E (pt)	1993-11-09	2004-07-30	Targeted Genetics Corp	Criacao de elevados titulos de vectores de aav recombinantes
US7252989B1 (en)	1994-04-04	2007-08-07	Board Of Regents, The University Of Texas System	Adenovirus supervector system
JPH10501686A (ja)	1994-04-13	1998-02-17	ザロックフェラーユニヴァーシティ	神経系の細胞へのｄｎａのａａｖ仲介送達
WO1997039789A1 (en)	1996-04-22	1997-10-30	Medtronic, Inc.	Two-stage angled venous cannula
US6544785B1 (en)	1998-09-14	2003-04-08	Mount Sinai School Of Medicine Of New York University	Helper-free rescue of recombinant negative strand RNA viruses
AU1775901A (en) *	1999-11-17	2001-05-30	Avigen, Inc.	Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
US20030165481A1 (en) *	2000-02-24	2003-09-04	Hersh Louis B.	Amyloid peptide inactivating enzyme to treat Alzheimer's disease
EP1319082B1 (en)	2000-09-18	2005-11-16	Genzyme Corporation	Expression vectors containing hybrid ubiquitin promoters
US20030050273A1 (en) *	2001-08-29	2003-03-13	Keiya Ozawa	Compositions and methods for treating neurodegenerative diseases
US7232670B2 (en) *	2001-09-28	2007-06-19	St. Jude Children's Research Hospital	Targeting proteins to cells expressing mannose receptors via expression in insect cells
PT2359869T (pt)	2001-12-17	2019-04-16	Univ Pennsylvania	Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
US6998118B2 (en)	2001-12-21	2006-02-14	The Salk Institute For Biological Studies	Targeted retrograde gene delivery for neuronal protection
AU2002364221B2 (en)	2001-12-21	2008-07-10	The Salk Institute For Biological Studies	Targeted retrograde gene delivery to motor neurons
WO2003100031A2 (en) *	2002-05-20	2003-12-04	Board Of Regents, The University Of Texas System	Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
US20040258666A1 (en) *	2003-05-01	2004-12-23	Passini Marco A.	Gene therapy for neurometabolic disorders
SI1620133T1 (sl) *	2003-05-01	2016-03-31	Genzyme Corporation	Genska terapija za nevrometabolne motnje
US7740168B2 (en)	2003-08-18	2010-06-22	Visa U.S.A. Inc.	Method and system for generating a dynamic verification value
WO2005035743A1 (fr) *	2003-10-15	2005-04-21	Vector Gene Technology Company Ltd.	Procede de production, d'isolation, de purification et utilisations de vecteurs virus adeno-associes recombinants multi-types
EP1716870A1 (en)	2005-04-29	2006-11-02	Bracco Imaging S.p.A.	MRI contrast agents endowed with concentration independent responsiveness
DK1879623T3 (da)	2005-05-02	2012-12-17	Genzyme Corp	Genterapi til rygmarvssygdomme
WO2006119458A1 (en)	2005-05-02	2006-11-09	Genzyme Corporation	Gene therapy for neurometabolic disorders
DK1986661T3 (da)	2006-02-08	2019-01-02	Genzyme Corp	Genterapi mod niemann-picks sygdom type a
US20150030561A1 (en)	2011-05-16	2015-01-29	Genzyme Corp.	Use of CXCR4 Antagonists
TWI821227B (zh)	2017-12-22	2023-11-11	美商健臻公司	胺甲喋呤誘發的免疫耐受性之生物標記

2006
- 2006-05-02 WO PCT/US2006/017242 patent/WO2006119458A1/en active Application Filing
- 2006-05-02 CN CN201611031204.7A patent/CN107007842A/zh active Pending
- 2006-05-02 EP EP19153520.2A patent/EP3520823B1/en active Active
- 2006-05-02 AT AT06759081T patent/ATE525092T1/de not_active IP Right Cessation
- 2006-05-02 CA CA2607173A patent/CA2607173C/en active Active
- 2006-05-02 PL PL06759081T patent/PL1879624T3/pl unknown
- 2006-05-02 PL PL11169633.2T patent/PL2420256T3/pl unknown
- 2006-05-02 JP JP2008510224A patent/JP5829372B2/ja active Active
- 2006-05-02 ES ES19153520T patent/ES2887076T3/es active Active
- 2006-05-02 EP EP16162716.1A patent/EP3058959B1/en active Active
- 2006-05-02 CN CN201410483749.6A patent/CN104306986A/zh active Pending
- 2006-05-02 CN CNA2006800237754A patent/CN101212988A/zh active Pending
- 2006-05-02 PT PT16162716T patent/PT3058959T/pt unknown
- 2006-05-02 PL PL16162716T patent/PL3058959T3/pl unknown
- 2006-05-02 PL PL19153520T patent/PL3520823T3/pl unknown
- 2006-05-02 EP EP06759081A patent/EP1879624B1/en active Active
- 2006-05-02 BR BRPI0611379-6A patent/BRPI0611379A2/pt not_active Application Discontinuation
- 2006-05-02 CA CA2998603A patent/CA2998603C/en active Active
- 2006-05-02 EP EP11169633.2A patent/EP2420256B1/en active Active
- 2006-05-02 CN CN201710506914.9A patent/CN107362371A/zh active Pending
- 2006-05-02 AU AU2006243776A patent/AU2006243776A1/en not_active Abandoned
- 2006-05-02 PT PT06759081T patent/PT1879624E/pt unknown
- 2006-05-02 PT PT19153520T patent/PT3520823T/pt unknown
- 2006-05-02 PT PT111696332T patent/PT2420256T/pt unknown
2007
- 2007-11-01 IL IL187078A patent/IL187078A/en not_active IP Right Cessation
- 2007-11-02 US US11/934,325 patent/US10632213B2/en active Active
2013
- 2013-09-27 JP JP2013201138A patent/JP2014037418A/ja active Pending
2015
- 2015-06-03 IL IL239167A patent/IL239167A0/en unknown
- 2015-10-02 JP JP2015197051A patent/JP6338560B2/ja active Active
2020
- 2020-03-03 US US16/808,206 patent/US11957765B2/en active Active

Also Published As

Publication number	Publication date
EP3520823B1 (en)	2021-06-30
IL187078A (en)	2015-06-30
CN104306986A (zh)	2015-01-28
US20080292593A1 (en)	2008-11-27
EP1879624B1 (en)	2011-09-21
CN107362371A (zh)	2017-11-21
EP3058959B1 (en)	2019-01-30
ES2887076T3 (es)	2021-12-21
BRPI0611379A2 (pt)	2010-08-31
JP2014037418A (ja)	2014-02-27
US11957765B2 (en)	2024-04-16
PT2420256T (pt)	2016-09-13
EP2420256A1 (en)	2012-02-22
US10632213B2 (en)	2020-04-28
CN107007842A (zh)	2017-08-04
US20200306387A1 (en)	2020-10-01
JP2016041706A (ja)	2016-03-31
CA2998603A1 (en)	2006-11-09
PL3058959T3 (pl)	2019-07-31
WO2006119458A9 (en)	2007-02-15
CN101212988A (zh)	2008-07-02
EP3058959A1 (en)	2016-08-24
EP3520823A1 (en)	2019-08-07
EP2420256B1 (en)	2016-06-22
WO2006119458A1 (en)	2006-11-09
US20140356327A9 (en)	2014-12-04
PT3520823T (pt)	2021-09-16
IL187078A0 (en)	2008-02-09
JP2008540445A (ja)	2008-11-20
CA2607173C (en)	2018-04-24
CA2998603C (en)	2019-07-23
AU2006243776A1 (en)	2006-11-09
PT3058959T (pt)	2019-05-24
IL239167A0 (en)	2015-07-30
PL3520823T3 (pl)	2021-11-22
EP1879624A4 (en)	2009-03-25
JP5829372B2 (ja)	2015-12-09
PL1879624T3 (pl)	2012-02-29
PT1879624E (pt)	2012-02-02
ATE525092T1 (de)	2011-10-15
JP6338560B2 (ja)	2018-06-06
EP1879624A1 (en)	2008-01-23
CA2607173A1 (en)	2006-11-09

Publication	Publication Date	Title
PL1879624T3 (pl)	2012-02-29	Terapia genowa dla zaburzeń neurometabolicznych
WO2005120581A3 (en)	2006-08-24	Gene therapy for neurometabolic disorders
MX2012005131A (es)	2012-05-29	Enfoques terapeuticos nuevos para tratar la enfermedad de alzheimer.
Snyder et al.	2004	Taking stock and planning for the next decade: realistic prospects for stem cell therapies for the nervous system
PH12020551180A1 (en)	2021-06-07	Methods and compositions for therapeutic protein delivery
UA92472C2 (ru)	2010-11-10	Фармацевтическая композиция, которая содержит 4-{4-[3-(4-хлор-3-трифторметилфенил)-уреидо]- 3-фторфенокси}-пиридин-2-карбоновой кислоты метиламид (варианты), способ получения твердой дисперсии указанного соединения и способ лечения с применением указанного соединения (варианты)
MX2021012184A (es)	2022-01-24	Terapias genicas para trastornos lisosomales.
MX2009002816A (es)	2009-05-28	Proteinas de fusion de albumina.
PT1782825E (pt)	2014-11-04	Tratamento de doenças de armazenanto de glicogénio tipo ii
WO2007118245A8 (en)	2008-10-02	Methods and compositions related to adenoassociated virus-phage particles
Kim et al.	2014	Amyotrophic lateral sclerosis-cell based therapy and novel therapeutic development
WO2006083797A3 (en)	2008-10-30	Improving and protecting cell therapy for neurological disorders including parkinson's disease
WO2007132292A3 (en)	2008-06-12	Therapy for alzheimer's disease
Gao et al.	2023	Enhancement of neural regeneration as a therapeutic strategy for Alzheimer's disease
WO2002007774A3 (en)	2003-01-16	Methods for therapy of neurodegenerative disease of the brain
WO2006057945A3 (en)	2006-11-09	2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2022029322A3 (en)	2022-04-28	Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
EP1149917A3 (en)	2001-11-14	Hepatitis B virus vectors for gene therapy
BR0317132A (pt)	2005-10-25	Métodos de diagnóstico e tratamento de doença pulmonar intersticial
WO2001020025A3 (en)	2001-10-11	Polymorphisms in the human cyp3a4 and cyp3a7 genes and their use in diagnostic and therapeutic applications
Sousa et al.	2023	Attenuation of ferroptosis as a potential therapeutic target for neuropsychiatric manifestations of post-COVID syndrome
EP1786474A4 (en)	2008-11-19	COMBINED GENE THERAPY FOR THE TREATMENT OF MACROSCOPIC GLIOMES
MX2023001562A (es)	2023-05-03	Terapias genicas para trastornos lisosomales.
MX2023006153A (es)	2023-07-18	Terapias genicas para enfermedad neurodegenerativa.
WO2005074605A3 (en)	2006-05-26	Recombinant molecular products for expression of heme oxygenase-1, heme oxygenase-2, and/or biliverdin reductase for treatment of neurodegenerative diseases or disorders